A Phase 1/2 interventional study of G1T38 and Osimertinib in Carcinoma, Non-Small-Cell Lung, Lung Cancer and Non-small Cell Lung Cancer, sponsored by G1 Therapeutics, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 523 open to participants now, 895 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,997th largest by enrollment of the 3,000 interventional ones that give a count, is one of 161 that started in 2018, is one of 487 in phase 1/2, and was the 1,997th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →523 of the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,415 · Phase 2 1,595 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 161 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 3,000 interventional studies, 100 across the 246 observational. Of the 2,301 that completed or were terminated, 1,053 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,740 of 3,373 have an industry lead sponsor. The 10 most frequent:
This study is registered under G1 Therapeutics, Inc., one of the names counted as Pharmacosmos A/S. Under that name alone:
G1 Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Pharmacosmos A/S has 2 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
269 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987956Phase 3Medicine Invention Design, IncPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
Add all 269 to your calendar (.ics) → With an account.
Among the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.
The study was an open-label design, planned to consist of 2 parts: a safety, pharmacokinetic, and dose-finding portion (Part 1), and a randomized portion (Part 2). Both parts were to include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase began on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 144 patients were planned to be enrolled in the study.
Part 2, the Phase 2 part of the study, was not conducted due to changes in corporate strategy. There were no safety signals identified in Phase 1/Part 1 that would have precluded the conduct of Part 2. As a result, 30 out of the planned 144 patients were enrolled.
All tumor assessments were conducted by the Investigators or site radiologist. In order to reduce the burden to the patients, data of overall survival (OS) were no longer required (since 29 January 2020). No OS analysis was conducted for Part 1 due to limited data in Part 1.
PK data for Cohorts 4 (150 BID) and 5 (200 BID) were not analyzed as they were deemed unnecessary, as the PK data from Cohorts 1-3 were sufficient to achieve the secondary study objective of assessing the effect of osimertinib on PK parameters of G1T38.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
Drug: G1T38 · Drug: Osimertinib
Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
Drug: G1T38 · Drug: Osimertinib
Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
Drug: G1T38 · Drug: Osimertinib
Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
Drug: G1T38 · Drug: Osimertinib
Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
Drug: G1T38 · Drug: Osimertinib
CDK 4/6 inhibitor
Also known as: Lerociclib
EGFR TKI; 80 mg
Also known as: Tagrisso
Dose Limiting Toxicity
The percentage of patients experiencing DLTs in Part 1 of the study in each cohort, including: * Grade 4 neutropenia * ≥ Grade 3 neutropenic infection/febrile neutropenia * Grade 4 thrombocytopenia * ≥ Grade 3 thrombocytopenia with bleeding * ≥ Grade 3 nonhematologic toxicity (additional criteria for nausea, vomiting, diarrhea, or fatigue: lasting \> 5 days with maximal medical management) * Liver function test abnormalities meeting Hy's Law criteria (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] ≥ 3 × upper limit of normal \[ULN\] and total bilirubin ≥ 2 × ULN).
Time frame: Cycle 1 Day -16 to Cycle 1 Day 28
Progression Free Survival (PFS)
Median time (months) and 95% CI from date of first dose of study drug/randomization until date of documented disease progression or death due to any cause. Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines for tumor assessments were used to determine progression. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Time frame: 36 months
Best Overall Tumor Response
The percentage of patients who fall into each category of Best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. When no imaging/measurement is done, the patient is not evaluable (NE); and if only a subset of lesion measurements are made, usually the case is also considered NE.
Time frame: 21 months
Pharmacokinetics of G1T38 and Metabolite G1T30: Maximum Plasma Concentration (Cmax)
The observed peak plasma concentration determined from the plasma concentration versus time data.
Time frame: Part 1, Cycle 1 Day -16 to Day -2.
Pharmacokinetics of G1T38 and Metabolite G1T30: Area Under Curve - Plasma Concentration (AUC) Infinity
Area under the concentration-time curve from time zero extrapolated to infinity using the linear-up log-down trapezoidal rule.
Time frame: Part 1, Cycle 1 Day -16 to Day -2.
Pharmacokinetics of G1T38 and Metabolite G1T30: Plasma: Terminal Half Life (T1/2)
Terminal half-life, defined as 0.693 divided by the terminal phase rate constant by λz , determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.
Time frame: Part 1, Cycle 1 Day -16 to Day -2.
Pharmacokinetics of G1T38: Plasma - Volume of Distribution
Volume of distribution in the terminal elimination phase, calculated as: Vz/F = (CL/F)/λz
Time frame: Part 1, Cycle 1 Day -16 to Day -2.
| Milestone | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| Started | 7 | 6 | 4 | 7 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 4 | 7 | 6 |
| Withdrew: Death | 2 | 3 | 2 | 4 | 2 |
| Withdrew: Study terminated and patients did not have progressive disease or died | 5 | 3 | 2 | 2 | 3 |
| Withdrew: Disease progression | 0 | 0 | 0 | 1 | 1 |
The percentage of patients experiencing DLTs in Part 1 of the study in each cohort, including: * Grade 4 neutropenia * ≥ Grade 3 neutropenic infection/febrile neutropenia * Grade 4 thrombocytopenia * ≥ Grade 3 thrombocytopenia with bleeding * ≥ Grade 3 nonhematologic toxicity (additional criteria for nausea, vomiting, diarrhea, or fatigue: lasting \> 5 days with maximal medical management) * Liver function test abnormalities meeting Hy's Law criteria (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] ≥ 3 × upper limit of normal \[ULN\] and total bilirubin ≥ 2 × ULN).
| Participants | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| Dose Limiting Toxicity | 0 | 0 | 1 | 0 | 0 |
Median time (months) and 95% CI from date of first dose of study drug/randomization until date of documented disease progression or death due to any cause. Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines for tumor assessments were used to determine progression. Progressive Disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
| months | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 19.3 (2.0 to NA) | 6.0 (1.8 to NA) | 1.4 (0.7 to NA) | 7.2 (1.6 to NA) | 12.9 (3.6 to NA) |
The percentage of patients who fall into each category of Best overall response (BOR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 guidelines. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. When no imaging/measurement is done, the patient is not evaluable (NE); and if only a subset of lesion measurements are made, usually the case is also considered NE.
| Participants | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 0 | 0 | 0 |
| Partial Response (PR) | 2 | 1 | 0 | 1 | 3 |
| Stable Disease (SD) | 2 | 4 | 1 | 3 | 0 |
| Progressive Disease (PD) | 1 | 1 | 3 | 2 | 1 |
| Not Evaluable (NE) | 1 | 0 | 0 | 1 | 1 |
The observed peak plasma concentration determined from the plasma concentration versus time data.
| ng/mL | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD |
|---|---|---|---|
| G1T38 Cycle 1 Day -16 | 27.229 ± 8.936 | 33.375 ± 12.212 | 43.850 ± 21.942 |
| G1T38 Cycle 1 Day -2 | 17.257 ± 1.471 | 26.400 ± 2.689 | 42.700 ± 25.107 |
| Metabolite G1T30 Cycle 1 Day -16 | 3.080 ± 1.301 | 3.568 ± 0.633 | 4.220 ± 1.717 |
| Metabolite G1T30 Cycle 1 Day -2 | 2.736 ± 0.764 | 3.853 ± 1.146 | 5.970 ± 4.369 |
Area under the concentration-time curve from time zero extrapolated to infinity using the linear-up log-down trapezoidal rule.
| h*ng/mL | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD |
|---|---|---|---|
| G1T38 Cycle 1 Day -16 | 319.6 ± 107 | 391.0 ± 85.6 | 715.6 ± 359 |
| G1T38 Cycle 1 Day -2 | 277.4 ± 63.2 | 390.0 ± 91.0 | 802.3 ± 519 |
| Metabolite G1T30 Cycle 1 Day -16 | 28.443 ± 17.175 | 30.853 ± 10.577 | 53.971 ± 23.638 |
| Metabolite G1T30 Cycle 1 Day -2 | 30.110 ± 11.255 | 44.745 ± 13.929 | 80.145 ± 66.239 |
Terminal half-life, defined as 0.693 divided by the terminal phase rate constant by λz , determined by linear regression of at least 3 points on the terminal phase of the log-linear plasma concentration-time curve.
| hour | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD |
|---|---|---|---|
| G1T38 Cycle 1 Day -16 | 13.83 ± 1.95 | 16.30 ± 4.36 | 15.59 ± 2.12 |
| G1T38 Cycle 1 Day -2 | 13.59 ± 2.88 | 12.61 ± 1.71 | 13.93 ± 2.14 |
| Metabolite G1T30 Cycle 1 Day -16 | 11.771 ± 7.248 | 12.238 ± 8.072 | 22.614 ± 3.297 |
| Metabolite G1T30 Cycle 1 Day -2 | 13.722 ± 8.025 | 18.220 ± 2.027 | 18.582 ± 2.977 |
Volume of distribution in the terminal elimination phase, calculated as: Vz/F = (CL/F)/λz
| Liter | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD |
|---|---|---|---|
| G1T38 Cycle 1 Day -16 | 14000 ± 6540 | 18700 ± 6910 | 15900 ± 9210 |
| G1T38 Cycle 1 Day -2 | 14900 ± 4660 | 14800 ± 5060 | 12900 ± 6490 |
Collected over The SAE reporting period started at the time of informed consent and the AE reporting period started from the time of first dose of study drug; both were assessed through 30 calendar days after the last administration of lerociclib/osimertnib, an average of 11 months for each participant (Mean exposure + 30 days/1 month).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1 Lerociclib at 200 mg QD | 2/7 (28.6%) | 2/7 (28.6%) | 7/7 (100%) |
| Part 1: Cohort 2 Lerociclib at 300 mg QD | 3/6 (50%) | 1/6 (16.7%) | 6/6 (100%) |
| Part 1: Cohort 3 Lerociclib at 400 mg QD | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Part 1: Cohort 4 Lerociclib at 150 mg BID | 4/7 (57.1%) | 0/7 (0%) | 7/7 (100%) |
| Part 1: Cohort 5 Lerociclib at 200 mg BID | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/7 | 0/6 | 1/4 | 0/7 | 0/6 |
| SepsisInfections and infestations | 0/7 | 0/6 | 0/4 | 0/7 | 1/6 |
| Ischaemic strokeNervous system disorders | 0/7 | 1/6 | 0/4 | 0/7 | 0/6 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/7 | 0/6 | 0/4 | 0/7 | 1/6 |
| COVID-19 pneumoniaInfections and infestations | 1/7 | 0/6 | 0/4 | 0/7 | 0/6 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/7 | 0/6 | 0/4 | 0/7 | 0/6 |
| Event | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/7 | 6/6 | 4/4 | 6/7 | 6/6 |
| NauseaGastrointestinal disorders | 5/7 | 5/6 | 3/4 | 2/7 | 3/6 |
| AnaemiaBlood and lymphatic system disorders | 5/7 | 2/6 | 2/4 | 1/7 | 0/6 |
| VomitingGastrointestinal disorders | 5/7 | 4/6 | 2/4 | 1/7 | 2/6 |
| Neutrophil count decreasedInvestigations | 5/7 | 1/6 | 2/4 | 2/7 | 0/6 |
| HeadacheNervous system disorders | 5/7 | 1/6 | 1/4 | 2/7 | 1/6 |
| LeukopeniaBlood and lymphatic system disorders | 4/7 | 2/6 | 1/4 | 1/7 | 0/6 |
| NeutropeniaBlood and lymphatic system disorders | 4/7 | 3/6 | 1/4 | 2/7 | 0/6 |
| Transaminases increasedInvestigations | 4/7 | 0/6 | 0/4 | 0/7 | 0/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/7 | 1/6 | 0/4 | 1/7 | 0/6 |
All enrolled patients who were administered at least 1 dose of study drug.
| Age, Continuous(years) | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID | Total |
|---|---|---|---|---|---|---|
| Mean | 62.71 ± 11.265 | 62.67 ± 8.779 | 62.75 ± 7.805 | 61.43 ± 15.757 | 66.17 ± 3.764 | 63.10 ± 10.118 |
| Sex: Female, Male(Participants) | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 3 | 3 | 5 | 4 | 21 |
| Male | 1 | 3 | 1 | 2 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 1 | 0 | 4 |
| Not Hispanic or Latino | 3 | 6 | 3 | 5 | 6 | 23 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Part 1: Cohort 1 Lerociclib at 200 mg QD | Part 1: Cohort 2 Lerociclib at 300 mg QD | Part 1: Cohort 3 Lerociclib at 400 mg QD | Part 1: Cohort 4 Lerociclib at 150 mg BID | Part 1: Cohort 5 Lerociclib at 200 mg BID | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 1 | 3 |
| White | 1 | 5 | 2 | 3 | 4 | 15 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 0 | 1 | 2 | 0 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Dec 2021, 44 months.
Results were first posted in May 2023, 1 year 4 months after primary completion.
Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 44 months is below that.
Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lerociclib
Carcinoma, Non-Small-Cell Lung →